Global Alpha-1 Antitrypsin Drugs Market 2018-2022

Below are a few of the insights on the market for the treatment of emphysema found in Technavio’s market research report

Improving diagnosis of Alpha-1 antitrypsin deficiency is a major factor driving the market growth

Technavio’s analysts have identified the improving techniques for testing for alpha-1 antitrypsin deficiency as the major factor to drive the market during the forecast period. As alpha-1 antitrypsin deficiency is difficult to diagnose, better methods for testing for alpha-1 antitrypsin deficiency have been in huge demand in the recent past fuelling the growth of the alpha-1 antitrypsin drugs market in the next five years. Several awareness programs for the treatment of emphysema have been launched in the past few years and this is going to contribute to the growth of the market in the coming few years. These driving factors are part of the reason why the market is expected to grow at a CAGR of almost 11%. For a complete list of drivers influencing the market’s growth, purchase Technavio’s full report.

Want to know what goes into a Technavio report? Get a FREE sample to see selected illustrations and analysis straight from this report.

Shire, CSL, and GRIFOLS are among the leading alpha-1 antitrypsin drugs manufacturers in the world

The global alpha-1 antitrypsin drugs market is growing moderately fragmented with the presence of few international and regional companies that offer products for the treatment of emphysema with the help of alpha-1 antitrypsin drugs. By offering a complete analysis of the market’s competitive landscape and with information on the products offered by the companies, this alpha-1 antitrypsin drugs industry analysis report will aid clients to identify new growth opportunities and design innovative strategies for business expansion.

The report offers a complete analysis of several alpha-1 antitrypsin drugs manufacturers, including:

• Shire
• CSL
• Grifols
• Kamada

The Americas will be the primary driver of growth during the forecast period

Technavio’s market research report covers the following regions:

• The Americas
• EMEA
• APAC

Over 63% of the market’s incremental growth is expected to come from the Americas over the next five years. In 2017, the Americas accounted for the largest market share in the global alpha-1 antitrypsin drugs market, followed by EMEA and APAC. However, the Americas and APAC will witness a decline in their market share over the next five years while the EMEA will register a steady growth in the market share held by the region in the global alpha-1 antitrypsin drugs market.

Key highlights of the global alpha-1 antitrypsin drugs market for the forecast years 2018-2022:

• CAGR of the market during the forecast period 2018-2022
• Detailed information on factors that will accelerate the growth of the alpha-1 antitrypsin drugs market during the next five years
• Precise estimation of the alpha-1 antitrypsin drugs market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the alpha-1 antitrypsin drugs industry across various geographies such as the Americas, EMEA, and APAC
• A thorough analysis of the market’s competitive landscape and detailed information on several vendors
• Comprehensive information about factors that will challenge the growth of alpha-1 antitrypsin drugs manufacturers

Get more value with Technavio’s subscription platform! Gain easy access to all of Technavio’s reports, along with on-demand services.     

Start your 14-day FREE trial

This market research report analyzes the market outlook and provides a list of key trends, drivers, and challenges that are anticipated to impact the global alpha-1 antitrypsin drugs market and its stakeholders over the forecast years.

Technavio’s analysts for the alpha-1 antitrypsin drugs market have also considered how the performance of other related markets in the vertical will impact the size of this market until 2022. Some of the markets most likely to influence the growth of the alpha-1 antitrypsin drugs market over the coming years are the respiratory drugs market and the cystic fibrosis therapeutics market.

Technavio also provides customized reports based on the specific requirement of our clients.